Sign in
Taking people in United StatesNo phase

Tests melatonin for sleep and thinking in people with cirrhosis and hepatic encephalopathy

Tests nightly melatonin against thiamine for sleep and thinking in adults with cirrhosis.

Key facts

Who runs it
Weill Medical College of Cornell University
Where
New York, United StatesSee the site
Trial code
Registry title
Affect of Melatonin on Sleep and Cognition in Cirrhosis
Status
Recruiting
People taking part
18 people, planned
Started
5 Aug 2025
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Melatonin tablet 3 mg once daily
  • Thiamine
Record updated
29 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cirrhosis and hepatic encephalopathy (or mild, hidden confusion from liver disease) who sleep badly. It tests melatonin against thiamine.

Age
Adults over age 18
Sex
All sexes can join
Disease stage
Cirrhosis with significant portal hypertension or decompensation (Baveno VII criteria); covert hepatic encephalopathy (PHES ≤ -4) or earlier diagnosed hepatic encephalopathy
Earlier treatment
People who regularly take melatonin 3 times a week must be able and willing to stop it for the study
Biomarker or test result
Disturbed sleep with a Pittsburgh Sleep Quality Index (PSQI) score of 5 or more

Main reasons for not taking part

  • Cannot give informed consent
  • Heavy current alcohol use (more than 7 drinks a week for women, 14 for men)
  • Body mass index over 40
  • Known sleep disorder, including obstructive sleep apnea
  • Pregnancy reported at screening

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria [de Franchis R et al 2022]
  • Adults over age 18
  • CHE (defined by PHES≤ -4) or previously diagnosed HE
  • Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5
  • Possession of a "smart phone" with Bluetooth capability and ability to download the Oura application (Apple iOS version 14.0 or greater or Android version 8.0 or higher)

Who cannot take part

  • Known prior sleep disorder including obstructive sleep apnea
  • Use of melatonin regularly (3x per week) if unable/unwilling to discontinue for the study
  • Inability provide informed consent
  • Heavy current alcohol use (>7 drinks weekly for women and 14 drinks weekly for men)'; -- Body mass index >40
  • Use of other prescription neuromodulating sleep aides
  • Self-reported pregnancy during study screening, as sleep physiology is different in this population

Where in United States

  • NewYork-Presbyterian Weill Cornell Medical CenterNew York, United StatesContact: Adam P Buckholz, MD MSTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn the affect of melatonin on sleep, cognitive function, and quality of life (QoL) in patients with cirrhosis and a complication called hepatic encephalopathy (HE). The main questions this study aims to answer are:

Read full original descriptionShow less

* Does taking melatonin increase REM sleep, an important part of healthy sleep that is reduced in cirrhosis? * Does taking melatonin improve cognitive function and reported QoL?

This is a pilot study, where participants will:

* take one month of melatonin, followed by one month of thiamine, which is another supplement but is not suspected to impact sleep significantly. * Undergo cognitive testing and take surveys * Wear a commercial wearable sleep tracker * Have a formal sleep study and salivary melatonin collection at the end of taking each supplement at our sleep center Participants will be blinded, and neither they nor the researchers will know which supplement they are taking first and which they are taking second. They will also be randomized, with half starting with melatonin and the other half starting with thiamine.

The 2 groups in the trial

  • Melatonin then ThiamineTreatment being tested

    This group will take one month of melatonin, followed by a one week washout period, then one month of thiamine. They will have the primary outcomes assessed at each month, and will also undergo continuous sleep monitoring via a wearable tracker during all phases of the arm.

    Treatment: Melatonin tablet 3 mg once daily and Thiamine

  • Thiamine then melatoninTreatment being tested

    This group will take one month of melatonin, followed by a one week washout period, then one month of thiamine. They will have the primary outcomes assessed at each month, and will also undergo continuous sleep monitoring via a wearable tracker during all phases of the arm.

    Treatment: Melatonin tablet 3 mg once daily and Thiamine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial
Plain-language title
Tests melatonin for sleep and thinking in people with cirrhosis and hepatic encephalopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 July 2026